Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 4, 2017, Pages 261-270

  Bally, Lia ^a,b,c   Thabit, Hood ^a,b   Kojzar, Harald ^d   Mader, Julia K ^d   Qerimi Hyseni, Jehona ^d   Hartnell, Sara ^b   Tauschmann, Martin ^a   Allen, Janet M ^a   Wilinska, Malgorzata E ^a   Pieber, Thomas R ^d   Evans, Mark L ^a,b   Hovorka, Roman ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF BERN   (Switzerland)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLOSED LOOP INSULIN DELIVERY; CONTROLLED STUDY; CONVENTIONAL INSULIN PUMP THERAPY; CROSSOVER PROCEDURE; DISEASE DURATION; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; INTERMETHOD COMPARISON; MALE; OPEN STUDY; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; IMPLANTABLE INFUSION PUMP; MIDDLE AGED; TIME FACTOR; TREATMENT OUTCOME;

ADULT; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INFUSION PUMPS, IMPLANTABLE; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 85009371921     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30001-3     Document Type: Article

References (31)

1. 1 American Diabetes Association. Approaches to glycemic treatment. Diabetes Care 39:suppl 1 (2016), S52–S59.
2. 2 Pedersen-Bjergaard, U, Kristensen, PL, Beck-Nielsen, H, et al. Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial. Lancet Diabetes Endocrinol 2 (2014), 553–561.
3. 3 UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 50 (2007), 1140–1147.
4. 4 Cryer, PE, Diverse causes of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 350 (2004), 2272–2279.
5. 5 Frier, BM, Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol 10 (2014), 711–722.
6. 6 Battelino, T, Conget, I, Olsen, B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 55 (2012), 3155–3162.
7. 7 van Beers, CA, DeVries, JH, Kleijer, SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol 4 (2016), 893–901.
8. 8 Bergenstal, RM, Klonoff, DC, Garg, SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 369 (2013), 224–232.
9. 9 Maahs, DM, Calhoun, P, Buckingham, BA, et al. A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes. Diabetes Care 37 (2014), 1885–1891.
10. 10 Ly, TT, Nicholas, JA, Retterath, A, Lim, EM, Davis, EA, Jones, TW, Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA 310 (2013), 1240–1247.
11. 11 Ruan, Y, Thabit, H, Leelarathna, L, et al. Variability of insulin requirements over 12 weeks of closed-loop insulin delivery in adults with type 1 diabetes. Diabetes Care 39 (2016), 830–832.
12. 12 Thabit, H, Hovorka, R, Coming of age: the artificial pancreas for type 1 diabetes. Diabetologia 59 (2016), 1795–1805.
13. 13 Thabit, H, Tauschmann, M, Allen, JM, et al. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med 373 (2015), 2129–2140.
14. 14 Tauschmann, M, Allen, JM, Wilinska, ME, et al. Day-and-night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care 39 (2016), 2019–2025.
15. 15 Stewart, ZA, Wilinska, ME, Hartnell, S, et al. Closed-loop insulin delivery during pregnancy in women with type 1 diabetes. N Engl J Med 375 (2016), 644–654.
16. 16 Kropff, J, Del Favero, S, Place, J, et al. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol 3 (2015), 939–947.
17. 17 Hovorka, R, Shojaee-Moradie, F, Carroll, PV, et al. Partitioning glucose distribution/transport, disposal, and endogenous production during IVGTT. Am J Physiol Endocrinol Metab 282 (2002), E992–1007.
18. 18 Wilinska, ME, Chassin, LJ, Acerini, CL, Allen, JM, Dunger, DB, Hovorka, R, Simulation environment to evaluate closed-loop insulin delivery systems in type 1 diabetes. J Diabetes Sci Technol 4 (2010), 132–144.
19. 19 Bolinder, J, Antuna, R, Geelhoed-Duijvestijn, P, Kröger, J, Weitgasser, R, Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 388 (2016), 2254–2263.
20. 20 Russell, SJ, Beck, RW, Design considerations for artificial pancreas pivotal studies. Diabetes Care 39 (2016), 1161–1167.
21. 21 Wilinska, ME, Budiman, ES, Taub, MB, et al. Overnight closed-loop insulin delivery with model predictive control: assessment of hypoglycemia and hyperglycemia risk using simulation studies. J Diabetes Sci Technol 3 (2009), 1109–1120.
22. 22 Maahs, DM, Buckingham, BA, Castle, JR, et al. Outcome measures for artificial pancreas clinical trials: a consensus report. Diabetes Care 39 (2016), 1175–1179.
23. 23 Kovatchev, BP, Cox, DJ, Gonder-Frederick, LA, Young-Hyman, D, Schlundt, D, Clarke, W, Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care 21 (1998), 1870–1875.
24. 24 Leelarathna, L, Dellweg, S, Mader, JK, et al. Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three-center randomized crossover study. Diabetes Care 37 (2014), 1931–1937.
25. 25 Khunti, K, Davies, M, Majeed, A, Thorsted, BL, Wolden, ML, Paul, SK, Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care 38 (2015), 316–322.
26. 26 Workgroup on Hypoglycemia American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 28 (2005), 1245–1249.
27. 27 Kilpatrick, ES, Rigby, AS, Goode, K, Atkin, SL, Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 50 (2007), 2553–2561.
28. 28 Schisano, B, Tripathi, G, McGee, K, McTernan, PG, Ceriello, A, Glucose oscillations, more than constant high glucose, induce p53 activation and a metabolic memory in human endothelial cells. Diabetologia 54 (2011), 1219–1226.
29. 29 Foos, V, Varol, N, Curtis, BH, et al. Economic impact of severe and non-severe hypoglycemia in patients with type 1 and type 2 diabetes in the United States. J Med Econ 18 (2015), 420–432.
30. 30 Russell, SJ, El-Khatib, FH, Sinha, M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 371 (2014), 313–325.
31. 31 Bergenstal, RM, Garg, S, Weinzimer, SA, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 316 (2016), 1407–1408.